Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.
Coerver EME, Fung WH, de Beukelaar J, Bouvy WH, Canta LR, Gerlach OHH, Hoitsma E, Hoogervorst ELJ, de Jong BA, Kalkers NF, van Kempen ZLE, Lövenich H, van Munster CEP, van Oosten BW, Smolders J, Vennegoor A, Zeinstra EMPE, Barrantes-Cepas M, Kooij G, Schoonheim MM, Lissenberg-Witte BI, Teunissen CE, Moraal B, Barkhof F, Uitdehaag BMJ, Mostert J, Killestein J, Strijbis EMM. Coerver EME, et al. JAMA Neurol. 2024 Dec 9. doi: 10.1001/jamaneurol.2024.4164. Online ahead of print. JAMA Neurol. 2024. PMID: 39652340
The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.
Coerver E, Schoof L, Hogenboom L, Wessels M, van Ruyven P, van Samkar A, Mostert J, van Kempen Z, van Oosten BW, Wokke BH, Tallantyre E, Myhr KM, Torkildsen O, Killestein J, Smets I, Strijbis E. Coerver E, et al. Mult Scler Relat Disord. 2024 Nov;91:105900. doi: 10.1016/j.msard.2024.105900. Epub 2024 Sep 28. Mult Scler Relat Disord. 2024. PMID: 39369631 Free article.
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.
Coerver EM, Kaçar S, Ciccarelli O, Sormani MP, Barkhof F, Arnold DL, Schoonheim MM, Van Kempen ZL, Mostert J, Koch MW, Killestein J, Eshaghi A, Uitdehaag BM, Strijbis EM. Coerver EM, et al. Mult Scler. 2024 Sep;30(10):1296-1308. doi: 10.1177/13524585241272938. Epub 2024 Sep 8. Mult Scler. 2024. PMID: 39245991 Free PMC article.
Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
Noteboom S, Strijbis EMM, Coerver EME, Colato E, van Kempen ZLE, Jasperse B, Vrenken H, Killestein J, Schoonheim MM, Steenwijk MD. Noteboom S, et al. Among authors: coerver eme. Mult Scler Relat Disord. 2024 Jul;87:105670. doi: 10.1016/j.msard.2024.105670. Epub 2024 May 10. Mult Scler Relat Disord. 2024. PMID: 38772150 Free article.
Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort.
de Ruiter LRJ, Loonstra FC, Jelgerhuis JR, Coerver EME, Toorop AA, van Leeuwen ICE, Noteboom S, Moraal B, Strijbis EMM, Schoonheim MM, Uitdehaag BMJ. de Ruiter LRJ, et al. Among authors: coerver eme. Mult Scler Relat Disord. 2023 Mar;71:104568. doi: 10.1016/j.msard.2023.104568. Epub 2023 Feb 12. Mult Scler Relat Disord. 2023. PMID: 36805177 Free article.
13 results